Results from the clinical trial demonstrated that the use of iC9/CAR.19/IL-15 NK cells targeting CD19-positive lymphoid malignancies is safe and effective in patients with CD19+ CLL and B-cell lymphoma [46]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.